Table A1.

BCR-ABL1 Ratios at Baseline and Month 3^*

Characteristic	Baseline		Month 3
	No.	%	No.	%
All patients (N = 237)
No. of patients	202†		237
BCR-ABL1 transcript level
Mean	75.5		25.6
SD	133.1		39.6
Median	40.2		11.6
25th to 75th percentiles	19.5-72.0		1.1-30.7
Minimum to maximum	0.0-1,243		0.0-241
BCR-ABL1 ratio
> 0.1% to 1%	5	2.5	31	13.1
> 1% to 10%	17	8.4	55	23.2
> 10%	176	87.1	123	51.9
Patients with baseline mutation (n = 86)‡
No. of patients	74†		86
BCR-ABL1 transcript level
Mean	92.8		34.9
SD	165.7		45.5
Median	41.9		19.4
25th to 75th percentiles	28.5-78.2		7.6-40.4
Minimum to maximum	1.9-1,243		0.0-236
BCR-ABL1 ratio
> 0.1% to 1%	0	0	7	8.1
> 1% to 10%	3	4.1	19	22.1
> 10%	71	95.9	57	66.3
Patients without baseline mutation (n = 132)‡
No. of patients	123†		132
BCR-ABL1 transcript level
Mean	66.2		20.0
SD	111.6		34.1
Median	35.8		5.6
25th to 75th percentiles	13.9-64.9		0.3-27.3
Minimum to maximum	0.0-931		0.0-241
BCR-ABL1 ratio
> 0.1% to 1%	5	4.1	21	15.9
> 1% to 10%	14	11.4	29	22.0
> 10%	100	81.3	58	43.9
Resistant patients (n = 165)
No. of patients	140†	165
BCR-ABL1 transcript level
Mean	85.4		28.5
SD	152.1		39.9
Median	41.4		14.9
25th to 75th percentiles	23.6-77.6		2.4-34.9
Minimum to maximum	0.0-1,243		0.0-236
BCR-ABL1 ratio
> 0.1% to 1%	2	1.4	16	9.7
> 1% to 10%	11	7.9	40	24.2
> 10%	126	90	94	57.0
Intolerant patients (n = 72)
No. of patients	62†	72
BCR-ABL1 transcript level
Mean	53.4		18.7
SD	70.2		38.2
Median	36.5		2.6
25th to 75th percentiles	16.3-54.0		0.3-25.6
Minimum to maximum	0.0-375		0.0-241
BCR-ABL1 ratio
> 0.1% to 1%	3	4.8	15	20.8
> 1% to 10%	6	9.7	15	20.8
> 10%	50	80.6	29	40.3

Abbreviation: SD, standard deviation.

^*According to International Scale.

^†35 patients (12 with baseline mutation, nine without, 25 resistant, 10 intolerant) had missing BCR-ABL1 assessments at baseline.

^‡19 patients had missing mutation analyses at baseline.